MET as a target in papillary renal cell carcinoma

Abstract

The biology underlying papillary renal cell carcinoma (pRCC) is largely unknown, and no specific therapies have been developed for advanced disease. The elucidation of the MET pathway status in types I and II pRCC may help to select patients who are more likely to benefit from MET inhibitors. © 2014 American Association for Cancer Research.